A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV

Completed · Phase 2

Conditions studied: HIV Infections

In brief

To determine the safety and anti-HIV activity of two doses of SC-49483 in combination with zidovudine (AZT) versus AZT alone. To determine the influences of viral phenotype on the anti-HIV activity of these treatment regimens. SC-49483 has no inherent activity against HIV-1 but is converted in the intestinal wall to SC-48334, which has demonstrated anti-HIV activity. Since SC-49483 causes significantly less gastrointestinal toxicity than SC-48334, the combination of SC-49483 with AZT may improve the benefits of both drugs in patients with HIV infection.

Key facts

Study ID

NCT00000791

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

210

Expected to finish

1995-07-01

Last updated by the study team

2021-10-28

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Medication:
• Required:
• PCP prophylaxis (trimethoprim/sulfamethoxazole, dapsone, or aerosolized pentamidine) in patients with CD4 count <= 200 cells/mm3.
• Allowed:
• Topical antifungal agents, ketoconazole, fluconazole, and itraconazole for candidiasis or disseminated fungal infections, as medically indicated.
• Maintenance therapy for Mycobacteria disease with isoniazid, ethambutol, rifampin, pyrazinamide, clofazimine, ciprofloxacin, clarithromycin, or rifabutin.
• Maintenance therapy for toxoplasmosis with pyrimethamine, sulfadiazine, or clindamycin.
• Maintenance therapy for herpes simplex virus with acyclovir at <= 1000 mg/day.
• Recombinant erythropoietin and G-CSF, if indicated.
• Antibiotics for bacterial infections.
• Symptomatic treatment such as antipyretics, analgesics, nonsteroidal anti-inflammatory agents, and antiemetics.
• Concurrent Treatment:
• Allowed:
• Localized radiation therapy and limited intralesional therapy for cutaneous Kaposi's sarcoma.
• Patients must have:
• Documented HIV infection.
• Per 07/19/94 amendment, one of the following:
• CD4 count 150 - 350 cells/mm3 within 60 days prior to study entry AND prior AZT for no more than 12 months cumulative (given with or without ddI or ddC).
• CD4 count 50 - 350 cells/mm3 within 60 days prior to study entry AND no prior antiretroviral therapy.
• MT-2 cell assay within 60 days prior to study entry.
• NOTE:
• Minimal Kaposi's sarcoma is permitted.

You may not qualify if…

• Co-existing Condition:
• Patients with the following condition are excluded:
• Malignancy other than minimal Kaposi's sarcoma.
• Concurrent Medication:
• Excluded:
• Antiretroviral therapies (other than study drug).
• Biologic response modifiers.
• Systemic corticosteroids for > 21 consecutive days.
• Foscarnet.
• Systemic cytotoxic chemotherapy for a malignancy.
• Patients with the following prior conditions are excluded:
• History of cataracts.
• History of intolerance to AZT at <= 600 mg/day.
• Unexplained temperature >= 38.5 degrees C that persists for any 7 days within the 30 days prior to study entry.
• Chronic diarrhea (defined as >= 3 stools per day) that persists for any 15 days within the 30 days prior to study entry.
• Prior Medication:
• Excluded:
• More than 6 months (more than 12 months per 07/19/94 amendment) cumulative prior therapy with AZT.
• Prior induction or maintenance therapy with foscarnet.
• Any investigational drug within 30 days prior to study entry.
• Prior SC-49483 or SC-48334.
• Prior ddC, ddI, or stavudine (d4T) as monotherapy.
• Interferon or interleukin within 30 days prior to study entry.
• Prior non-nucleoside reverse transcriptase inhibitors (e.g., NVP, ATV).
• Systemic corticosteroids for > 21 consecutive days.

Where it is running

• Alabama Therapeutics CRS — Birmingham, Alabama, United States
• USC CRS — Los Angeles, California, United States
• Stanford CRS — Palo Alto, California, United States
• Ucsf Aids Crs — San Francisco, California, United States
• University of Colorado Hospital CRS — Aurora, Colorado, United States
• Univ. of Miami AIDS CRS — Miami, Florida, United States
• Northwestern University CRS — Chicago, Illinois, United States
• Rush Univ. Med. Ctr. ACTG CRS — Chicago, Illinois, United States
• Weiss Memorial Hosp. — Chicago, Illinois, United States
• Cook County Hosp. CORE Ctr. — Chicago, Illinois, United States
• Indiana Univ. School of Medicine, Infectious Disease Research Clinic — Indianapolis, Indiana, United States
• Methodist Hosp. of Indiana — Indianapolis, Indiana, United States
• St. Louis ConnectCare, Infectious Diseases Clinic — St Louis, Missouri, United States
• Washington U CRS — St Louis, Missouri, United States
• SUNY - Buffalo, Erie County Medical Ctr. — Buffalo, New York, United States
• Beth Israel Med. Ctr. (Mt. Sinai) — New York, New York, United States
• Univ. of Rochester ACTG CRS — Rochester, New York, United States
• Unc Aids Crs — Chapel Hill, North Carolina, United States
• Wake County Health and Human Services CRS — Raleigh, North Carolina, United States
• Univ. of Cincinnati CRS — Cincinnati, Ohio, United States
• Hosp. of the Univ. of Pennsylvania CRS — Philadelphia, Pennsylvania, United States
• University of Washington AIDS CRS — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.